Literature DB >> 11241257

Equal care ensures equal survival for African-American women with cervical carcinoma.

J H Farley1, J F Hines, R R Taylor, J W Carlson, M F Parker, E R Kost, S J Rogers, T A Harrison, C I Macri, G P Parham.   

Abstract

BACKGROUND: [corrected] It was the purpose of this study to investigate whether race is an independent prognostic factor in the survival of patients with cervical carcinoma in a health care system with minimal racial bias, and few barriers to access to care.
METHODS: Records for patients with a diagnosis of invasive cervical carcinoma from 1988 to 1999 were obtained from the Automated Central Tumor Registry for the United States Military Health Care System. Clinical data including race, age at diagnosis, histology, grade, stage, socioeconomic status, treatment modality, and survival also were obtained. Survival analysis was performed with Kaplan-Meier survival curves.
RESULTS: One thousand five hundred fifty-three patients were obtained for review. Sixty-five percent of patients were Caucasian, and 35% were minorities. Of the minorities, 29% were African Americans (AAs). Mean age of diagnosis was similar among AAs and Caucasians, 44 and 42 years, respectively. There was no statistically significant difference between the distribution of age, stage, grade, or histology between Caucasians and AAs. Forty-six percent of patients were treated with surgery and 56% with radiation therapy, with no difference in type of treatment between the Caucasian and AA groups. Five- and 10-year survival rates for Caucasians and AAs were 75%, and 76%, and 64% 65% (P = 0.59), respectively.
CONCLUSIONS: In an equal access, unbiased, nonracial environment, race is not an independent predictor of survival for patients with cervical carcinoma. This study has shown, for the first time to the authors' knowledge, that when they receive equal treatment for cervical carcinoma, AA women's survival can approach that of their nonminority counterparts (75% at 10 years). Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11241257

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.

Authors:  Bradley J Monk; Chunqiao Tian; Peter G Rose; Rachelle Lanciano
Journal:  Gynecol Oncol       Date:  2007-02-02       Impact factor: 5.482

2.  Ethnic disparities in cervical cancer survival among Texas women.

Authors:  Ann L Coker; Christopher P Desimone; Katherine S Eggleston; Arica L White; Melanie Williams
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

3.  First psychiatric hospitalizations in the US military: the National Collaborative Study of Early Psychosis and Suicide (NCSEPS).

Authors:  Richard Herrell; Ioline D Henter; Ramin Mojtabai; John J Bartko; Diane Venable; Ezra Susser; Kathleen R Merikangas; Richard J Wyatt
Journal:  Psychol Med       Date:  2006-07-31       Impact factor: 7.723

Review 4.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

5.  Cervical cancer screening in a sexually transmitted disease clinic: screening adoption experiences from a midwestern clinic.

Authors:  Beth E Meyerson; M Aaron Sayegh; Alissa Davis; Janet N Arno; Gregory D Zimet; Ann M LeMonte; James A Williams; Lynn Barclay; Barbara Van Der Pol
Journal:  Am J Public Health       Date:  2015-02-17       Impact factor: 9.308

6.  Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?

Authors:  David A Barrington; Sarah E Dilley; Emily E Landers; Eric D Thomas; Jonathon D Boone; J Michael Straughn; Gerald McGwin; Charles A Leath
Journal:  Gynecol Oncol       Date:  2016-10-06       Impact factor: 5.482

7.  Gynecologic cancer outcomes in the elderly poor: A population-based study.

Authors:  Kemi M Doll; Ke Meng; Ethan M Basch; Paola A Gehrig; Wendy R Brewster; Anne-Marie Meyer
Journal:  Cancer       Date:  2015-07-31       Impact factor: 6.860

8.  Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

Authors:  Krishnansu S Tewari; Michael W Sill; Bradley J Monk; Richard T Penson; Harry J Long; Andrés Poveda; Lisa M Landrum; Mario M Leitao; Jubilee Brown; Thomas J A Reid; Helen E Michael; David H Moore
Journal:  Clin Cancer Res       Date:  2015-12-15       Impact factor: 12.531

9.  Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB-IIA Cervical Cancer in California.

Authors:  Krista S Pfaendler; Jenny Chang; Argyrios Ziogas; Robert E Bristow; Kristine R Penner
Journal:  Obstet Gynecol       Date:  2018-05       Impact factor: 7.661

Review 10.  Too many women are dying from cervix cancer: Problems and solutions.

Authors:  David K Gaffney; Mia Hashibe; Deanna Kepka; Kathryn A Maurer; Theresa L Werner
Journal:  Gynecol Oncol       Date:  2018-10-06       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.